Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Qualitative Immunoglobulin G Assays : The Value of Numeric Reporting
CONTEXT.—: Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) immunoglobulin G (IgG) testing is used for serosurveillance and will be important to evaluate vaccination status. Given the urgency to release coronavirus disease 2019 (COVID-19) serology tests, most manufacturers have developed qualitative tests.
OBJECTIVE.—: To evaluate clinical performance of 6 different SARS-CoV-2 IgG assays and their quantitative results to better elucidate the clinical role of serology testing in COVID-19.
DESIGN.—: Six SARS-CoV-2 IgG assays were tested using remnant specimens from 190 patients. Sensitivity and specificity were evaluated for each assay with the current manufacturer's cutoff and a lower cutoff. A numeric result analysis and discrepancy analysis were performed.
RESULTS.—: Specificity was higher than 93% for all assays, and sensitivity was higher than 80% for all assays (≥7 days post-polymerase chain reaction testing). Inpatients with more severe disease had higher numeric values compared with health care workers with mild or moderate disease. Several discrepant serology results were those just below the manufacturers' cutoff.
CONCLUSIONS.—: Severe acute respiratory syndrome coronavirus 2 IgG antibody testing can aid in the diagnosis of COVID-19, especially with negative polymerase chain reaction. Quantitative COVID-19 IgG results are important to better understand the immunologic response and disease course of this novel virus and to assess immunity as part of future vaccination programs.
Medienart: |
E-Artikel |
---|
Erscheinungsjahr: |
2021 |
---|---|
Erschienen: |
2021 |
Enthalten in: |
Zur Gesamtaufnahme - volume:145 |
---|---|
Enthalten in: |
Archives of pathology & laboratory medicine - 145(2021), 8 vom: 01. Aug., Seite 929-936 |
Sprache: |
Englisch |
---|
Beteiligte Personen: |
Forest, Stefanie K [VerfasserIn] |
---|
Links: |
---|
Themen: |
Antibodies, Viral |
---|
Anmerkungen: |
Date Completed 23.09.2021 Date Revised 23.09.2021 published: Print Citation Status MEDLINE |
---|
doi: |
10.5858/arpa.2020-0851-SA |
---|
funding: |
|
---|---|
Förderinstitution / Projekttitel: |
|
PPN (Katalog-ID): |
NLM323773095 |
---|
LEADER | 01000naa a22002652 4500 | ||
---|---|---|---|
001 | NLM323773095 | ||
003 | DE-627 | ||
005 | 20231225184911.0 | ||
007 | cr uuu---uuuuu | ||
008 | 231225s2021 xx |||||o 00| ||eng c | ||
024 | 7 | |a 10.5858/arpa.2020-0851-SA |2 doi | |
028 | 5 | 2 | |a pubmed24n1079.xml |
035 | |a (DE-627)NLM323773095 | ||
035 | |a (NLM)33821952 | ||
040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
041 | |a eng | ||
100 | 1 | |a Forest, Stefanie K |e verfasserin |4 aut | |
245 | 1 | 0 | |a Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Qualitative Immunoglobulin G Assays |b The Value of Numeric Reporting |
264 | 1 | |c 2021 | |
336 | |a Text |b txt |2 rdacontent | ||
337 | |a ƒaComputermedien |b c |2 rdamedia | ||
338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
500 | |a Date Completed 23.09.2021 | ||
500 | |a Date Revised 23.09.2021 | ||
500 | |a published: Print | ||
500 | |a Citation Status MEDLINE | ||
520 | |a CONTEXT.—: Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) immunoglobulin G (IgG) testing is used for serosurveillance and will be important to evaluate vaccination status. Given the urgency to release coronavirus disease 2019 (COVID-19) serology tests, most manufacturers have developed qualitative tests | ||
520 | |a OBJECTIVE.—: To evaluate clinical performance of 6 different SARS-CoV-2 IgG assays and their quantitative results to better elucidate the clinical role of serology testing in COVID-19 | ||
520 | |a DESIGN.—: Six SARS-CoV-2 IgG assays were tested using remnant specimens from 190 patients. Sensitivity and specificity were evaluated for each assay with the current manufacturer's cutoff and a lower cutoff. A numeric result analysis and discrepancy analysis were performed | ||
520 | |a RESULTS.—: Specificity was higher than 93% for all assays, and sensitivity was higher than 80% for all assays (≥7 days post-polymerase chain reaction testing). Inpatients with more severe disease had higher numeric values compared with health care workers with mild or moderate disease. Several discrepant serology results were those just below the manufacturers' cutoff | ||
520 | |a CONCLUSIONS.—: Severe acute respiratory syndrome coronavirus 2 IgG antibody testing can aid in the diagnosis of COVID-19, especially with negative polymerase chain reaction. Quantitative COVID-19 IgG results are important to better understand the immunologic response and disease course of this novel virus and to assess immunity as part of future vaccination programs | ||
650 | 4 | |a Evaluation Study | |
650 | 4 | |a Journal Article | |
650 | 7 | |a Antibodies, Viral |2 NLM | |
650 | 7 | |a Immunoglobulin G |2 NLM | |
700 | 1 | |a Orner, Erika P |e verfasserin |4 aut | |
700 | 1 | |a Goldstein, D Yitzchak |e verfasserin |4 aut | |
700 | 1 | |a Wirchnianski, Ariel S |e verfasserin |4 aut | |
700 | 1 | |a Bortz, Robert H |e verfasserin |4 aut | |
700 | 1 | |a Laudermilch, Ethan |e verfasserin |4 aut | |
700 | 1 | |a Florez, Catalina |e verfasserin |4 aut | |
700 | 1 | |a Malonis, Ryan J |e verfasserin |4 aut | |
700 | 1 | |a Georgiev, George I |e verfasserin |4 aut | |
700 | 1 | |a Vergnolle, Olivia |e verfasserin |4 aut | |
700 | 1 | |a Lo, Yungtai |e verfasserin |4 aut | |
700 | 1 | |a Campbell, Sean T |e verfasserin |4 aut | |
700 | 1 | |a Barnhill, Jason |e verfasserin |4 aut | |
700 | 1 | |a Cadoff, Evan M |e verfasserin |4 aut | |
700 | 1 | |a Lai, Jonathan R |e verfasserin |4 aut | |
700 | 1 | |a Chandran, Kartik |e verfasserin |4 aut | |
700 | 1 | |a Weiss, Louis M |e verfasserin |4 aut | |
700 | 1 | |a Fox, Amy S |e verfasserin |4 aut | |
700 | 1 | |a Prystowsky, Michael B |e verfasserin |4 aut | |
700 | 1 | |a Wolgast, Lucia R |e verfasserin |4 aut | |
773 | 0 | 8 | |i Enthalten in |t Archives of pathology & laboratory medicine |d 1978 |g 145(2021), 8 vom: 01. Aug., Seite 929-936 |w (DE-627)NLM000037508 |x 1543-2165 |7 nnns |
773 | 1 | 8 | |g volume:145 |g year:2021 |g number:8 |g day:01 |g month:08 |g pages:929-936 |
856 | 4 | 0 | |u http://dx.doi.org/10.5858/arpa.2020-0851-SA |3 Volltext |
912 | |a GBV_USEFLAG_A | ||
912 | |a GBV_NLM | ||
951 | |a AR | ||
952 | |d 145 |j 2021 |e 8 |b 01 |c 08 |h 929-936 |